# Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma

> **NCT06030037** · PHASE2 · WITHDRAWN · sponsor: **Diwakar Davar**

## Conditions studied

- PD-1 Refractory Advanced Melanoma

## Interventions

- **BIOLOGICAL:** Healthy Donor Fecal Microbiota Transplantation (hdFMT)
- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06030037
- **Lead sponsor:** Diwakar Davar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-03-11
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial withdrawn per PI directive
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06030037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06030037, "Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06030037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*